進入內容區塊

國立陽明交通大學學生事務處

::: 網站導覽 回首頁 EN FB 本處單位 陽明交大
  • 字型大小-小
  • 字型大小-中
  • 字型大小-大
搜尋
展開選單

歷任學務長(陽明)

  • 更新日期：112-11-02
  • 發布單位：學生事務處
林姝君教授
林姝君教授
國立陽明交通大學教授
林姝君教授
 (02) 2826-7272
 
研究專長：
  • 腫瘤生物學
  • 分子生物學
  • 生物化學
研究方向：
  • 檳榔誘發之訊息活化於細胞轉型之角色
  • 微型RNA異常於口腔之起癌作用
研究計畫(三年內)：
  • 探討鐵凋亡抑制因子在口腔癌化過程及治療之角色(110-2314-B-A49A-515-MY3)
  • B7-H4配體在口腔癌調控癌化及免疫逃避之角色(108-2314-B-010-010-MY3)
研究計畫 (已結案)：
  • 探討抗微型RNA miR-31策略阻斷口腔癌進行與藥物拮抗之效益(107-2314-B-010-026-MY3)
  • B7-H4配體在口腔癌調控癌化及免疫逃避之角色(108-2314-B-010-010-MY3)
  • 針對FAM213A基因驅動口腔癌化及幹細胞化之功能探討(105-2314-B-010-027-MY3)
  • 研究在口腔癌化進程中第一型與AT序列互動結合功能蛋白區基因所扮演之角色及微RNA對其之調控機制(103-2314-B-010-020-MY3)
  • 以微型RNA轉殖鼠動物模式測試臨床前期口腔癌之防治
  • 微型RNA調控尼古丁乙醯膽鹼受器於菸草相關口腔癌化之角色    
  • 致癌性微型RNA及其標靶基因調節口腔上皮細胞功能及癌化之探討    
得獎紀錄：
  • 2018 指導林依宁同學獲口生所「碩二論文比賽」第一名
  • 2014 指導博士班學生陳怡芬獲學術論文研討會「基礎研究組」佳作    
  • 2014 指導口生所曾思學同學獲台灣葛蘭素史克口腔保健獎學金學術競賽首獎    
  • 2013 指導博士班學生曾思學榮獲101學年度「博士班研究生論文比賽」佳作    
  • 2011 指導口生所學生蔡孟妙榮獲本校100年度「陽明博士班優良論文獎學金」全校第一名
  • 2011 指導口生所碩士班學生沈妏霙獲頒本校100年度「紀念尹珣若先生品學及論文優良獎學金」
  • 2011 榮獲本校99學年度優良教師
  • 2010 指導牙醫系楊惇茹同學獲學術論文研討會大專生組優等獎    
  • 2010 指導蔡孟妙同學榮獲陽明大學學術海報競試佳作獎
  • 2007~2010 教師學術卓越獎勵
  • 2005~2009 牙醫學院教學認真獎    
  • 2009 指導蔡孟妙同學獲優秀壁報論文獎
  • 2009 指導牙醫系楊惇茹同學獲國科會大專學生參與專題研究計畫研究創作獎    
  • 2008 指導牙醫系黃彥娟同學榮獲中華牙醫學會學術競試冠軍  
  • 2008 指導洪佩詩同學獲貼示海報優等獎    
  • 2007 指導曾羽辛同學獲優秀壁報論文獎    
  • 2006 指導口生所洪佩詩同學榮獲陽明大學學術海報競試優等獎    
  • 2005 指導牙醫系郭璇憓同學榮獲中華牙醫學會學術競試冠軍    
期刊論文：
  • Chang KW, Hung WW, Chou CH, Tu HF, Chang SR,
  • Liu YC, Liu CJ, Lin SC* (2021, Aug). LncRNA MIR31HG drives oncogenicity by inhibiting the Limb-Bud and Heart Development gene (LBH) during oral carcinoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(8383):1-15. MOST 108-2314-B-010-011-MY3. 本人為通訊作者.
    Lin SC., Liu CJ, Ji SH, Hung WW, Liu YC, Chang SR, Tu HF, Chang KW* (2021, Aug). The upregulation of oncogenic miRNAs in swabbed samples obtained from oral premalignant and malignant lesions. Clinical Oral Investigations, 1-9. MOST 107-2314-B-010-032-MY3. 本人為第一作者.
  • Chang KW, Lin CE, Tu HF, Chung HY, Chen YF, Lin SC* (2020, Dec). Establishment of a p53 null murine oral carcinoma cell line and the identification of genetic alterations associated with this carcinoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21, E9354. MOST 107-2314-B-010-026-MY3. 本人為通訊作者.
  • Lin SC, Wu HL, Yeh LY, Yang CC, Kao SY, Chang KW* (2020, Dec). Activation of the miR-371/372/373 miRNA cluster enhances oncogenicity and drug resistance in oral carcinoma cells. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21, E9442. MOST 105-2314-B-010-029-MY3. 本人為第一作者.
  • Yeh LY, Yang CC, Wu HL, Kao SY, Liu CJ, Chen YF, Lin SC*, Chang KW* (2020, Jan). The miR-372-ZBTB7A oncogenic axis suppresses TRAIL-R2 associated drug sensitivity in oral carcinoma. Front Oncol, 10: 47. MOST 105-2314-B-010-029-MY3. 本人為通訊作者.
  • Chen YF, Chang KW, Yang IT, Tu HF, Lin SC* (2019, Jun). Establishment of syngeneic murine model for oral cancer therapy. Oral Oncology, 95: 194-201. MOST 102-2628-B-010-006-MY3. 本人為通訊作者.
  • Kao YY, Chen YF, Yeh LY, Chen YF, Chang KW, Liu CJ, Fan Chiang CY, Lin SC* (2019, May). MicroRNA miR-31 targets SIRT3 to disrupt mitochondrial activity and increase oxidative stress in oral carcinoma. Cancer Letters, 456: 40 – 48. MOST 102-2628-B-010-011-MY3. 本人為通訊作者.
  • Chen YF, Liu CJ, Lin LH, Chou CH, Yeh LY, Lin SC*, Chang, KW* (2019, Mar). Establishing of mouse oral carcinoma cell lines derived from transgenic mice and their use as syngeneic tumorigenesis models. BMC Cancer, 19 (1): 281. MOST 102-2628-B-010-006-MY3. 本人為通訊作者.
  • Chen YF, wei YY, Yang CC, Liu CJ, Yeh LY, Chou CH, Chang KW*, Lin SC* (2019, Feb). miR-125b suppresses oral oncogenicity by targeting the anti-oxidative gene PRXL2A. Redox Biology, 22: 101140. MOST 105-2314-B-010-027-MY3. 本人為通訊作者.
  • Lin SC, Lin LH, Yu SY, Kao SY, Chang KW, Cheng HW, Liu CJ*. (2018, Dec). FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival. Carcinogenesis, 39 (11)1320-30. MOST 102-2314-B-095-007-MY3. 本人為第一作者.
  • Peng SY, Tu HF, Yang CC, Wu CH, Liu CJ, Chang KW*, Lin SC*. (2018, Nov). miR-134 targets PDCD7 to reduce E-cadherin expression and enhance oral cancer progression.. Int J Cancer, 143(11): 2892-2904. MOST 104-2314-B-010-046-MY3. 本人為通訊作者.
  • Chou CH, Tu HF, Kao SY, Fan Chiang C-Y, Liu CJ, Chang KW*, Lin SC*. (2018, Apr). Targeting of miR-31/96/182 to the Numb gene during head and neck oncogenesis. Head and Neck, 40 (4): 808-817. MOST 102-2628-B-010-011-MY3. 本人為通訊作者.
  • Wang MC, Yeh YL, Shih MY, Li WC, Chang KW*, Lin SC* (2018, Apr). Portland cement induces human periodontal ligament cells to differentiate by upregulating miR-146a. J Form Med Ass, 117 (4): 308-315. 本人為通訊作者.
  • Liu CJ, Lin JS, Cheng HW, Hsu YH, Cheng CY, Lin SC* (2017, Apr). Plasma miR-187* is a potential biomarker for oral carcinoma. Clin Oral Invest, 21:1131– MOST 101-2314-B-010-050-MY3. 本人為通訊作者.
  • Lin SC, Kao SY, Chang JC, Liu YC, Yu EH, Tseng SH, Liu CJ, Chang KW (2016, Sep). Up-regulation of miR-187 modulates the advances of oral carcinoma by targeting BARX2 tumor suppressor. Oncotarget, 7(38): 61355-65. MOST 103-2314-B-010-024-MY3. 本人為第一作者.
  • Lu WC, Liu CJ, Tu HF, Chung YT, Yang CC, Kao SY, Chang KW, Lin SC (2016, Sep). miR-31 targets ARID1A and enhances the oncogenicity and stemness of head and neck squamous cell carcinoma. Oncotarget, 7(35): 51002-51016. MOST 102-2628-B-010-011-MY3. 本人為通訊作者.
  • Chen YF, Yang CC, Kao SY, Liu CJ, Lin SC, Chang KW (2016, Aug). MicroRNA-211 enhances the oncogenicity of carcinogen-induced oral carcinoma by repressing TCF12 and increasing antioxidant activity. Cancer Research, 76(16): 4872-86. MOST 102-2628-B-010-006-MY3. 本人為通訊作者.
  • Kao SY, Tsai MM, Wu CH, Chen JJ, Tseng SH, Lin SC,Chang KW (2016, Apr). Co-targeting of multiple microRNAs on factor-inhibiting hypoxia-inducible factor (FIH) gene for the pathogenesis of head and neck carcinomas . Head and Neck , 38(4):522-8. MOHW: 103-TD-B-111-02. 本人為通訊作者.
  • Kao YY, Tu HF, Kao SY, Chang KW, Lin SC (2015, Nov). The increase of oncogenic miRNA expression in tongue carcinogenesis of a mouse model. Oral Oncology, 51: 1103-12. MOST 102-2628-B-010-011-MY3. 本人為通訊作者.
  • Tseng SH, Yang CC, Yu EH, Chang C, Lee YS, Liu CJ, Chang KW*, Lin SC* (2015, Mar). K14-EGFP-miR-31 transgenic mice have high susceptibility to chemical-induced squamous cell tumorigenesis that is associating with Ku80 repression. Int J Cancer, 136(6): 1263-75. MOST 102-2628-B-010-011-MY3. 本人為通訊作者.
  • Yeh LY, Liu CJ, Wong YK, Chang C, Lin SC, Chang KW (2015, Jan). miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo . Oncotarget, 6: 6062-75. Taichung VGH : TCVGH-YM1010302. 本人為通訊作者.
  • Lu WC, Kao SY, Yang CC, Tu HF, Wu CH, Chang KW, Lin SC (2014, Aug). EGF Up-Regulates miR-31 through the C/EBPb Signal Cascade in Oral Carcinoma . PLOS ONE . MOST 102-2628-B-010-011-MY3. 本人為通訊作者.
  • Hung PS, Tu HF, Kao SY, Yang CC, Liu CJ, Huang TY, Chang KW, Lin SC. (2014, Jan). miR-31 is upregulated in oral premalignant epithelium and contributes to the immortalization of normal oral keratinocytes . Carcinogenesis, 35(5):1162-71. 台北榮總: VN99-05. 本人為通訊作者.
回上一頁
gotop